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The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer 
According to the Immunohistochemical Phenotypes
We studied the expression of BRCA1, ERCC1, and RRM1 which play an important role in 
DNA repair systems in breast cancer. Immunohistochemical staining for EGFR, BRCA1, 
ERCC1, and RRM1 were performed by using a tissue microarray made from 230 breast 
cancer patients. Patients were classified into luminal A, luminal B, HER-2, and triple 
negative breast cancer (TNBC) types according to ER, PR, and HER-2 expression. The 
expression of ERCC1, RRM1, and BRCA1 were correlated (P < 0.05). The expression level 
of ERCC1 was the lowest in TNBC type (P = 0.031), ERCC1 negativity was more prominent 
in TNBC and luminal B groups than luminal A and HER-2 groups (P = 0.013). Cases with 
EGFR overexpression showed high expression of RRM1 and BRCA1 (P = 0.046, and 0.004, 
respectively). In conclusion, the expression of ERCC1 is particularly lower in TNBCs than 
other types of breast cancers. 
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Breast cancer is one of the most heterogeneous tumors present-
ing various histology, behavior, and outcome. There are many 
different treatment modalities for breast cancer, including drug 
therapy according to the characteristics of the tumors after sur-
gery. Prototypes of drug therapy are tamoxifen for breast can-
cers that express hormone receptors and trastuzumab for those 
with HER-2 overexpression. However, there is no specific tar-
geted therapy for triple negative breast cancer (TNBC) without 
the expression of hormone receptors or HER-2 until now. 
 Possible targeted therapies for TNBC include cytotoxic che-
motherapy that causes interstrand breaks (platinum-based 
drugs) (1), PARP1 inhibitor (2), EGFR tyrosine kinase inhibitor 
(3), and c-kit tyrosine kinase inhibitor (3). Lately, clinical trials 
for cytotoxic chemotherapy that causes interstrand breaks have 
been conducted. Platinum-based chemotherapeutic agents 
cause DNA monoadducts and intrastrand cross-link (4), which 
induces normal cells to correct DNA adducts through DNA re-
pair systems. However, TNBCs have abundant DNA aberration, 
suggesting a defective DNA repair system (5). BRCA1 is one of 
the important factors in this DNA repair system. It is involved in 
homologous recombination repair, non-homologous repair, 
and nucleotide excision repair, which are critical DNA repair 
systems (6). Hereditary BRCA1-associated breast cancer with 
germ line mutation of BRCA1 gene accounts for only 5% of all 
breast cancers (7), and BRCA1 mutation is rare in sporadic breast 
cancers (8).
 However, there are considerable similarities in morphologic 
phenotypes and molecular features (e.g. ER negativity, high nu-
clear grade, high Ki-67 staining, CK5/6 expression, and EGFR 
expression) between sporadic TNBCs and BRCA1 related breast 
cancers related to BRCA1 mutation carrier (9, 10). Also, the pos-
sibility of dysfunctional BRCA1 pathway without BRCA1 somatic 
mutation in the sporadic breast cancer is raised by the findings 
of significantly low BRCA1 protein expression in ER(-), PR(-), 
and basal-like phenotypes, considerably low BRCA1 mRNA ex-
pression in basal-like sporadic breast cancers, and high level of 
ID4, a negative regulator of BRCA1, in sporadic basal-like breast 
cancers (11). 
 We examined the expression of BRCA1, ERCC1, and RRM1 
which play an important role in DNA repair systems in breast 
cancer according to immunohistochemical phenotypes and 
investigated a possibility of their predictive role in chemothera-
py that causes DNA interstrand breaks in breast cancer. 
MATERIALS AND METHODS
Patient selection
From the Department of Pathology of Severance Hospital, we 
retrieved tissue samples of patients with invasive ductal carci-
noma of the breast, which were filed between January 2000 and 
December 2001. Formalin-fixed and paraffin-embedded tissue 
specimens from 230 patients with primary breast cancer were 
included. All archival hematoxylin and eosin (H&E)–stained 
slides for each patient were reviewed by two pathologists. The 
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histological grade was assessed using the Nottingham grading 
system (12), and nuclear grade was evaluated according to the 
modified Black’s nuclear grade (1 = low grade, 2 = intermediate 
grade, and 3 = high grade) (13). Histologic parameters were eval-
uated using the H&E-stained slides. Histologic parameters such 
as histologic subtype, nuclear grade and histologic grade were 
evaluated using H&E-stained slides. Clinical parameters includ-
ed patient age at initial diagnosis, tumor stage of American Joint 
Committee on Cancer (AJCC) criteria, lymph node status, local 
recurrence, systemic recurrence, and patient survival. 
Tissue microarray
On each H&E-stained slide, a representative area was selected 
and a corresponding spot was marked on the surface of the par-
affin block. Using a biopsy needle, the selected area was punched 
out and a 3-mm tissue core was placed into a 6 × 5 recipient 
block. Two tissue cores of invasive component were extracted 
to minimize extraction bias. Each tissue core was assigned with 
a unique tissue microarray location number that was linked to 
a database containing other clinicopathologic data. 
Immunohistochemistry (IHC)
All immunostainings were performed using formalin-fixed, par-
affin-embedded tissue sections. Five micrometer-thick sections 
were obtained by using a microtome, transferred to adhesive 
slides, and dried at 62°C for 30 min. The sections were then placed 
in a glass jar with 10 mM citrate buffer (pH 6.0), and they were 
irradiated in a microwave oven for 15 min. The sections were 
allowed to cool in the jar at room temperature for 20 min. The 
slides were then rinsed with Tris buffered saline (TBS). A block-
ing reagent was added for 10 min after quenching the endoge-
nous peroxidase activity in 0.3% hydrogen peroxide for 10 min. 
After incubation with primary antibodies (EGFR [EGFR.25, 1:50, 
Novocastra, UK], BRAC1 [MS110, 1:100, Oncogene, UK], ERCC1 
[8F1, 1:100, Abcam, UK], and RRM1 [polyclonal, 1:100, Abcam, 
UK]), immunodetection was performed with biotinylated anti-
mouse immunoglobulin, followed by peroxidase-labeled strep-
tavidin using a labeled streptavidin biotin kit with 3,3´-diamino-
benzidine chromogen as substrate. Optimal primary antibody 
incubation time and concentration were determined via serial 
dilution for each immunohistochemical assay with an identical-
Table 1. Clinicopathologic characteristics of patients according to breast cancer phenotype
Parameters
Total  
(n = 230) (%)
TNBC 
(n = 60 ) (%)
HER-2  
(n = 28) (%)
Luminal A  
(n = 119 ) (%)
Luminal B  
(n = 23 ) (%)
P value
Age (yr, mean ± SD) 48.8 ± 10.7 47.2 ± 12.8 48.5 ± 9.4 49.4 ± 10.0 50.2 ± 10.0 0.567
Histologic subtype
   IDC, NOS
   Medullary 
   Metaplastic 
 
217 (94.3)
11 (4.8)
2 (0.9)
 
50 (83.3)
8 (13.3)
2 (3.3)
 
25 (89.3)
3 (10.7)
 
119 (100.0)
 
23 (100.0)
< 0.000
Nuclear grade
   1
   2
   3
 
15 (6.5)
129 (56.1)
86 (37.4)
 
1 (1.7)
21 (35.0)
38 (63.3)
 
 
12 (42.9)
16 (57.1)
 
12 (10.1)
82 (68.9)
25 (21.0)
 
2 (8.7)
14 (60.9)
7 (30.4)
< 0.000
Histologic grade
   I
   II
   III
 
34 (14.8)
123 (53.5)
73 (31.7)
 
3 (5.0)
23 (38.3)
34 (56.7)
 
 
12 (42.9)
16 (57.1)
 
26 (21.8)
74 (62.2)
19 (16.0)
 
5 (21.7)
14 (60.9)
4 (17.4)
< 0.000
Estrogen receptor 
   Positive 
   Negative 
 
134 (58.3)
96 (41.7)
 
 
60 (100.0)
 
 
28 (100.0)
 
114 (95.8)
5 (4.2)
 
20 (87.0)
3 (13.0)
< 0.000
Progesterone receptor 
   Positive 
   Negative 
 
97 (42.2)
133 (57.8)
 
 
60 (100.0)
 
 
28 (100.0)
 
86 (72.3)
33 (27.7)
 
11 (47.8)
12 (52.2)
< 0.000
AJCC stage
   I
   II
   III
 
52 (22.6)
132 (57.4)
46 (20.0)
 
14 (23.6)
39 (65.0)
7 (11.6)
 
4 (14.2)
17 (60.7)
7 (25.0)
 
30 (25.2)
64 (53.7)
25 (21.0)
 
4 (17.3)
12 (52.1)
7 (30.4)
0.392
HER-2 
   Positive
   Negative 
 
51 (22.2)
179 (77.8)
 
 
60 (100.0)
 
28 (100.0)
 
 
119 (100.0)
 
23 (100.0)
< 0.000
LN metastasis 101 (43.9) 19 (31.7) 12 (42.9) 59 (49.6) 11 (47.8) 0.147
The number of metastatic LN  
   (mean ± SD)
2.5 ± 7.0 1.0 ± 2.3 3.6 ± 7.2 2.6 ± 8.1 4.7 ± 8.6 0.135
Tumor recurrence 26 (11.3) 4 (6.7) 4 (14.3) 14 (11.8) 4 (17.4) 0.492
Distant metastasis 19 (8.3) 2 (3.3) 4 (14.3) 10 (8.4) 3 (13.0) 0.266
Patient death 13 (5.6) 4 (6.7) 4 (14.3) 4 (3.4) 1 (4.3) 0.147
Duration of clinical follow-up  
   (months, mean ± SD)
89.5 ± 23.5 85.2 ± 24.3 80.3 ± 33.7 93.1 ± 19.5 90.9 ± 22.9 0.057
IDC, NOS, invasive ductal carcinoma, not otherwise specified; AJCC, American Joint Committee on Cancer.
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ly fixed and embedded tissue block. Slides were counterstained 
using Harris hematoxylin. The staining was interpreted by two 
pathologists under a multiview microscope. Different results 
were discussed, and, in the case of persistent discordance, a third 
pathologist was consulted. EGFR staining was scored as follows: 
0 for no membrane staining; 1+ for faint, partial membrane stain-
ing; 2+ for weak, complete membrane staining in > 10% of tumor 
cells; and 3+ for intense complete membrane staining in > 10% 
of tumor cells. Tumors with a score of 2+ or 3+ were interpreted 
as positive for overexpression. 
 For evaluating the expression of BRCA1, ERCC1, and RRM1, 
the percentage of expressed tumor cells were examined. Nucle-
ar or cytoplasmic staining of more than 10% of the cells was con-
sidered positive expression. The percentage of expressed tumor 
cells was used as “expression index” in this study.
Tumor phenotype classification
In this study, we classified breast cancer phenotypes according 
to the immunohistochemistry and FISH results for ER, PR, and 
HER-2 as follows: luminal A type, ER or/and PR positive and 
HER-2 negative, luminal B type, ER or/and PR positive and HER-
2 overexpressed or/and amplified, HER-2 overexpression type, 
ER and PR negative and HER-2 overexpressed or/and ampli-
fied, and TNBC type, ER, PR, and HER-2 negative. 
Statistical analysis
Data were processed using SPSS for Windows, version 12.0 (SPSS 
Inc., Chicago, IL, USA). Student’s t and Fisher’s exact tests were 
used to examine any difference in continuous and categorical 
variables, respectively. Significance was assumed when P < 0.05. 
Kaplan-Meier survival curves and log-rank statistics were em-
ployed to evaluate time to tumor metastasis and time to survival. 
Multivariate regression analysis was performed using Cox pro-
portional hazards model.
H&E
TNBC Luminal AHER-2 Luminal B
EGFR
ERCC1
RRM1
BRCA1
Fig. 1. EGFR, ERCC1, RRM1, and BRCA1 immunohistochemistry result according to breast cancer phenotype. EGFR overexpression is noted in TNBC and HER-2 type. ERCC1 
negativity is observed in TNBC and luminal B. 
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Ethics statement
This study was approved by the Institutional Review Board (IRB) 
of Severance Hospital (4-2010-0136). The IRB exempted the in-
formed consent form.
RESULTS
Clinicopathologic features of breast cancer
Clinicopathologic characteristics of breast cancers in this study 
are summarized in Table 1. Sixty patients (26.0%) were classified 
as TNBCs, 28 patients (12.2%) as HER-2 types, 119 patients (51.7 
%) as luminal type A, and 23 patients as luminal type B (10.0%) 
in a total of 230 patients. Medullary carcinomas and metaplastic 
carcinomas were highly relevant to TNBCs (P < 0.001). TNBCs 
and HER-2 types show higher nuclear grade (P < 0.001), and 
TNBCs show higher histologic grade than other types (P < 0.001).
Immunohistochemical findings for EGFR, BRCA1, ERCC1, 
and RRM1 in breast cancer
The immunohistochemical stain results of EGFR, BRCA1, ERCC1, 
and RRM1 are shown in Fig. 1, and Table 2. EGFR overexpression 
was observed in 21 patients (9.1%). Fourteen of them (66.7%) 
were TNBC type, and no EGFR overexpression was observed in 
luminal type B (P < 0.001).
 ERCC1 positivity was higher in luminal type A (69.7%). In con-
trast, TNBC and luminal type B cancers tended to be negative 
for ERCC1 (51.7% and 56.5%, respectively, P = 0.013). RRM1 ex-
pression was not significantly different between the subtypes of 
breast cancers (P = 0.301). Cytoplasmic BRCA1 expression was 
noted in 84 (36.5%) cases and nuclear BRCA1 expression was 
noted in 57 (24.7%) cases. Cytoplasmic and nuclear BRCA1 ex-
Table 2. Immunohistochemical characteristics of patients according to breast cancer phenotype
Parameters
Total  
(n = 230) (%)
TNBC  
(n = 60 ) (%)
HER-2  
(n = 28 ) (%)
Luminal A  
(n = 119 ) (%)
Luminal B  
(n = 23 ) (%)
P value
EGFR 
   Positive 
   Negative 
 
21 (9.1)
209 (90.9)
 
14 (23.3)
46 (76.7)
 
  4 (14.3)
24 (85.7)
 
  3 (2.5)
116 (97.5)
 
 
23 (100)
< 0.000
 
 
ERCC1
   Positive 
   Negative 
 
138 (60.0)
  92 (40.0)
 
29 (48.3)
31 (51.7)
 
16 (57.1)
12 (42.9)
 
  83 (69.7)
  36 (30.3)
 
 10 (43.5)
 13 (56.5)
0.013
 
RRM1
   Positive 
   Negative 
 
204 (88.7)
  26 (11.3)
 
56 (93.3)
4 (6.7)
 
26 (92.9)
2 (7.1)
 
101 (84.9)
  18 (15.1)
 
 21 (91.3)
 2 (8.7)
0.301
 
 
BRCA1 (cytoplasm)
   Positive 
   Negative 
 
  84 (36.5)
146 (63.5)
 
19 (31.6)
41 (68.4)
 
14 (50.0)
14 (50.0)
 
  41 (34.4)
  78 (65.6)
 
 10 (43.4)
 13 (56.6)
0.320
BRCA1 (nuclei)
   Positive 
   Negative 
 
  57 (24.7)
173 (75.3)
 
  8 (13.3)
52 (86.7)
 
  8 (28.5)
20 (71.5)
 
  32 (26.8)
  87 (73.2)
 
   9 (39.1)
 14 (60.8)
0.064
ERCC1 EI (%, mean±SD) 23.4 ± 23.4 16.8 ± 21.4 25.0 ± 26.5 27.2 ± 22.7 19.1 ± 24.8 0.031
RRM1 EI (%, mean±SD) 43.7 ± 27.7 48.6 ± 27.9 58.9 ± 28.4 37.4 ± 26.0 44.7 ± 26.6 0.001
BRCA1 (cytoplasm) EI (%, mean ±SD) 12.8 ± 20.9 11.5 ± 21.6 20.0 ± 25.3 11.0 ± 18.7 16.0 ± 23.3 0.177
BRCA1 (nuclei) EI (%, mean ±SD)   7.9 ± 16.6   4.6 ± 12.8   9.4 ± 20.2   7.8 ± 15.6 14.7 ± 22.9 0.090
EI, expression index.
Table 3. The relation among EGFR, ERCC1, RRM1, and BRCA 1* expressions
EGFR status
P valueOverexpressed  
(n = 21)
Not overexpressed  
(n = 209)
ERCC1 EI (mean ± SD) 25.2 ± 22.4 23.2 ± 23.5 0.712
RRM1 EI (mean ± SD) 55.2 ± 26.9 42.5 ± 27.6 0.046
BRCA1 (cytoplasm) 
   EI (mean ± SD)
25.2 ± 29.7 11.5 ± 19.5 0.004
BRCA1 (nuclei) 
   EI (mean ± SD)
11.6 ± 22.8   7.5 ± 15.8 0.295
ERCC1 status
P value
Positive (n = 138) Negative (n = 92)
RRM1 EI (mean ± SD) 49.5 ± 26.2 35.0 ± 27.7 < 0.000
BRCA1 (cytoplasm) 
   EI (mean ± SD)
17.9 ± 22.6   5.0 ± 15.2 < 0.000
BRCA1 (nuclei)
   EI (mean ± SD)
10.5 ± 18.7   3.9 ± 11.7 0.003
RRM1 status
P value
Positive (n = 204) Negative (n = 26)
ERCC1 EI (mean ± SD) 24.8 ± 23.5 12.3 ± 19.8 0.010
BRCA1 (cytoplasm) 
   EI (mean ± SD)
13.8 ± 21.5   4.4 ± 12.8 0.031
BRCA1 (nuclei) 
   EI (mean ± SD)
  8.1 ± 16.8   6.1 ± 14.4 0.572
BRCA1 status (cytoplasm)
P value
Positive (n = 84) Negative (n = 146)
ERCC1 EI (mean ± SD) 35.8 ± 22.7 16.3 ± 20.7 < 0.000
RRM1 EI (mean ± SD) 54.2 ± 25.6 37.7 ± 27.2 < 0.000
BRCA1 status (nuclei)
P value
Positive (n = 57) Negative (n = 173)
ERCC1 EI (mean ± SD) 32.1 ± 24.7 20.5 ± 22.3 0.001
RRM1 EI (mean ± SD) 45.2 ± 25.9 43.2 ± 28.3 0.634
*Included only the cases with cytoplasmic expression of BRCA1 immunohistochemical 
stain. EI, expression index.
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pression were not significantly different between the subtypes 
of breast cancers (P = 0.320, and 0.064, respectively). 
 In analysis of ERCC1, RRM1, and BRCA1 by continuous vari-
able of expression index (%), ERCC1 showed the lowest mean 
for TNBCs and the highest mean for luminal type A (P = 0.031), 
and RRM1 showed the lowest mean for luminal type A and the 
highest mean for HER-2 type (P = 0.001). 
 The relation among EGFR, ERCC1, RRM1, and BRCA1 expres-
sions is shown in Table 3. RRM1 and cytoplasmic BRCA1 expres-
sion indices were higher when EGFR was overexpressed (P = 
0.046 and 0.004, respectively). The positivity of ERCC1, RRM1, 
and cytoplasmic BRCA1 were significantly related to each other 
(P < 0.05, Table 3). Nuclear BRCA1 expression index was signifi-
cantly higher when ERCC1 was positive (P = 0.003). Moreover, 
ERCC1, RRM1, and BRCA1 expression indices were significant-
ly related (Fig. 2).
Impact of clinicopathologic and immunohistochemical 
parameters on time to disease recurrence and time to 
overall survival
Disease free survival and overall survival according to clinico-
pathologic and immunohistochemical parameters are shown 
in Table 4. A group with lymph node metastasis showed shorter 
disease free survival (P = 0.009), and a group with positive estro-
gen receptor showed longer overall survival than negative estro-
gen receptor (P = 0.014). However, there was no relation among 
the expression of BRCA1, ERCC1, and RRM1, disease free sur-
vival, and overall survival.
DISCUSSION
In this study, EGFR overexpression was observed in 9.1% out of 
230 breast cancers and in 66.7% of TNBCs (P < 0.001). This could 
be expected from the fact that EGFR, like cytokeratin 5/6, is 
known as a surrogate marker of basal-like breast cancer (3), and 
basal-like breast cancers are fairly overlapped with TNBCs. EGFR 
overexpression rate in TNBCs has been reported to be 56%-84% 
(14, 15), which is higher than this study. However, it is difficult to 
directly compare others’ results with this study because different 
EGFR staining antibodies were used, thus different positive cri-
teria. In this study, there was no EGFR overexpression in lumi-
nal type A and type B, but 14.3% of HER-2 type breast cancers 
showed EGFR overexpression in this study. About 15%-45% of 
basal-like breast cancers classified by microarray-based expres-
sion profiling analysis can express one of ER, PR, and HER-2 in 
immunohistochemical staining (3, 16, 17). Therefore, not com-
Fig. 2. Correlation among ERCC1, RRM1, and BRCA1 expressions.
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Table 4. Univariate analysis of various clinicopathologic and immunohistochemical factors in breast cancers on time to recurrence-free survival and overall survival by log-rank test
Parameters
No. of patients (N = 230) (%) Recurrence-free survival Overall survival
No. of cases
Tumor 
recurrence
Patient death
Median survival 
(95% CI) months 
P value
Median survival 
(95% CI) months
P value
Histologic subtype
   IDC, NOS
   Medullary 
   Metaplastic 
 
217
11
2
 
  26 (12.0)
  0 (0.0)
  0 (0.0)
 
13 (6.0)
  0 (0.0)
  0 (0.0)
 
 104 (99-108)
n/a
n/a
0.507  
  110 (107-113)
n/a
n/a
0.756
Nuclear grade
   1
   2
   3
 
15
129
86
 
    2 (13.3)
  17 (13.2)
  7 (8.1)
 
  0 (0.0)
11 (8.5)
  2 (2.3)
 
   92 (76-108)
 103 (97-108)
 103 (98-108)
0.708  
n/a
  108 (105-112)
  111 (108-114)
0.217
Histologic grade
   I
   II
   III
 
34
123
73
 
  2 (5.8)
  17 (13.8)
  7 (9.6)
 
  1 (2.9)
  9 (7.3)
  3 (4.1)
 
 104 (95-112)
 102 (97-108)
 104 (97-111)
0.385  
  107 (101-113)
  109 (105-113)
  109 (105-113)
0.512
Estrogen receptor 
   Positive 
   Negative 
 
134
96
 
  17 (12.7)
  9 (9.4)
 
  4 (3.0)
  9 (9.3)
 
   105 (100-109)
 102 (95-109)
0.758  
  113 (111-115)
104 (99-110)
0.014
Progesterone receptor
   Positive 
   Negative 
 
97
133
 
  13 (13.4)
13 (9.8)
 
  5 (5.2)
  8 (6.0)
 
 105 (99-110)
 104 (98-110)
0.733  
  112 (109-115)
  109 (105-113)
0.569
HER-2 
   Positive
   Negative 
 
51
179
 
    8 (15.7)
  18 (10.1)
 
  5 (9.8)
  8 (4.4)
 
 101 (92-111)
   105 (101-110)
0.308  
106 (99-114)
  111 (109-114)
0.171
AJCC stage
   I
   II
   III
 
52
132
46
 
  3 (5.7)
  15 (11.3)
    8 (17.3)
 
  1 (1.9)
  8 (6.0)
  4 (8.6)
 
105.8 (101-111)
 103 (98-109)
   99 (90-108)
0.256  
  109 (106-111)
  109 (105-113)
  109 (105-112)
0.368
LN metastasis
   Present 
   Absent 
 
101
129
 
  18 (17.8)
  8 (6.2)
 
  9 (8.9)
  4 (3.1)
 
   96 (89-103)
   109 (105-113)
0.009  
  106 (102-111)
  112 (109-115)
0.073
EGFR 
   Positive 
   Negative 
 
21
209
 
  1 (4.8)
  25 (12.0)
 
  0 (0.0)
13 (6.2)
 
 103 (95-112)
   104 (100-108)
0.502  
n/a
  110 (107-113)
0.318
ERCC1
   Positive 
   Negative 
 
138
92
 
  19 (13.8)
  7 (7.6)
 
  9 (6.5)
  4 (4.3)
 
 103 (97-108)
   107 (101-113)
0.180  
  110 (106-113)
  111 (107-115)
0.477
RRM1
   Positive 
   Negative 
 
204
26
 
  24 (11.8)
  2 (7.7)
 
13 (6.4)
  0 (0.0)
 
 104 (99-108)
 106 (97-115)
0.498  
  110 (107-113)
n/a
0.181
BRCA1 (cytoplasm)
   Positive 
   Negative 
 
84
146
 
    9 (10.7)
  17 (11.6)
 
  2 (2.3)
11 (7.5)
 
 104 (97-111)
 104 (99-109)
0.911  
  112 (108-115)
  109 (105-112)
0.134
BRCA1 (nuclei)
   Positive 
   Negative 
 
57
173
 
    6 (10.5)
20
 
  1 (1.7)
12 (6.9)
 
 104 (96-113)
 104 (99-108)
0.962  
  113 (109-116)
  109 (106-112)
0.187
n/a, not available. AJCC, American Joint Committee on Cancer.
pletely coincident with TNBCs, basal-like breast cancers, which 
may show EGFR overexpression, can partly exist in HER-2 type.
 ERCC1 negativity was higher in TNBC and luminal type B 
than HER-2 and luminal type A (P = 0.013), and the expression 
index of ERCC1 was the lowest in TNBCs (P = 0.031). In particu-
lar, TNBCs without adequate targeted therapy besides surgery 
until now showed higher negativity rate for ERCC1 than that of 
all breast cancers. 
 ERCC1 is an endonuclease which plays an important role in 
repair of DNA double strand break (18). Recently, the correla-
tion between ERCC1 expression and repair of cisplatin-induced 
DNA adducts has been suggested (19, 20). ERCC1 has an ability 
to repair DNA adducts in the presence of platinum-based drugs 
such as cisplatin (21). Therefore, better therapeutic response can 
be expected for platinum-based drugs in tumors with low ERCC1 
expression. Actually, some reports have shown better response 
with platinum-based chemotherapy in the case of low ERCC1 
expression in human ovarian cancer cell line (22), gastric cancer 
(19), colorectal cancer (20), and especially, non-small cell lung 
cancer (23). However, to our knowledge, expression of ERCC1 
in breast cancers has not been sufficiently studied (24, 25).
 In this study, ERCC1 negativity rate was higher in TNBC com-
pared to all study population, and the expression index of ERCC1 
is lowest in TNBC. So, the possibility of the use of platinum-based 
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drug as treatment modality for TNBC can be expected which 
was supported by a phase II clinical trial for neoadjuvant cispla-
tin chemotherapy in 22 TNBC patients, showing almost 64% re-
sponse rate and 22% pathologically complete response (26). So, 
more clinical trials are needed to examine the correlation be-
tween ERCC1 expression and response to platinum-based drug 
therapy. 
 RRM1 and BRCA1 also have roles in DNA repair systems like 
ERCC1 does. In this study, RRM1 showed higher expression in-
dex than ERCC1 and BRCA1 in breast cancers. Previous study 
reported higher RRM1 protein expression than ERCC1 and 
BRCA1 in metastatic breast cancers (24). However, the direct 
comparison of the result of present study to that of previous 
study is difficult because previous study showed the expression 
range but this study demonstrated expression index. BRCA1 
was negative in 58.7% of breast cancers in this study. Consider-
ing that only 5% of all breast cancers were related to BRCA1 mu-
tation, the percentage of BRCA1 negative breast cancers in this 
study is very high. Previous reports on the correlation between 
BRCA1 gene status and BRCA1 immunohistochemistry showed 
that the sensitivity and specificity for BRCA1 gene mutation wide-
ly varied according to antibody type (27, 28). Since this means 
BRCA1 immunohistochemistry is a restrictive method to detect 
of BRCA1 gene mutation, it is inadequate to correlate immuno-
histochemical staining result for BRCA1 with BRCA1 gene mu-
tation status.
 We found that breast cancers with EGFR overexpression show 
higher expression rate of RRM1 and BRCA1 (P = 0.046, and 0.011, 
respectively), which is supported by a finding that EGFR-medi-
ated signal pathway up-regulates DNA repair proteins (29). Also, 
an analysis of 84 cases with cytoplasmic expression out of 96 
BRCA1 positive cases corresponds with a previous article show-
ing a significant relation between cytoplasmic BRCA1 expres-
sion on immunohistochemistry and EGFR expression (30). Not 
knowing the exact mechanisms, there seems to be a correlation 
between altered BRCA1 expression and EGFR overexpression. 
In addition, the altered BRCA1 expression was associated with 
shorter disease free survival (30). We found a significant corre-
lation between ERCC1, RRM1 and BRCA1 expression in this 
study, which is consistent with previous reports (24, 25). Defec-
tive BRCA1 genes caused up-regulation of RAD52 and XRCC4, 
and down-regulation of ERCC1 and RRM1 as a kind of compen-
sation (25).
 In conclusion, the expression of ERCC1, RRM1, and BRCA1 
are closely associated with one another in breast cancers. The 
expression of ERCC1 is particularly lower in TNBCs than other 
types of breast cancers. 
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AUTHOR SUMMARY
The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the 
Immunohistochemical Phenotypes
Dokyung Kim, Woohee Jung, and Ja Seung Koo
Hereditary breast cancer is associated with mutation of BRCA1, a DNA repair gene. We investigated the expression of DNA repair 
gene such as ERCC1, RRM1, and BRCA1 in breast cancer, particularly according to the immunohistochemical phenotype 
determined by the results of estrogen receptor, progesterone receptor, and HER-2. The triple negative breast cancer showed lower 
expression of ERCC1 than any other type breast cancer, which could be related to the role of ERCC1 as a predictable factor of 
platinum-based chemotherapy.
